Table 2.

Survival analyses—univariate analyses

Variable	Category	P
		PD‐IDC	IDC	PD‐DCIS	DCIS
Age at diagnosis (years)		<0.001	<0.001	<0.001	<0.001
Race	White	0.021	<0.001	0.134	<0.001
	Black
	Hispanic/Other/Unknown
Laterality	Left	0.619	0.004	0.070	0.442
	Right
Tumor location	Central/NAC	0.012	<0.001	0.192	0.009
	Upper inner quadrant
	Lower inner quadrant
	Upper outer quadrant
	Lower outer quadrant
	Overlapping lesion
Tumor grade	Grade I	<0.001	<0.001	0.005	0.006
	Grade II
	Grade III
	Grade IV
AJCC sixth edition stage	0	<0.001	<0.001	<0.001	—
	I
	II
	III
T	T0	<0.001	<0.001	0.002	—
	T1
	T2
	T3
	T4
N	N0	<0.001	<0.001	<0.001	—
	N1
	N2
	N3
Hormone receptor status	ER+/PR+	0.182	<0.001	0.371	<0.001
	ER+/PR‐
	ER‐/PR+
	ER‐/PR‐
HER2 statusa	Positive	0.788	0.013	0.643	0.692
	Negative
Molecular subtypea	HR+/Her2‐	0.196	<0.001	0.853	0.069
	HR+/Her2+
	HR‐/Her2+
	HR‐/Her2‐
Surgery	Partial mastectomy	0.004	<0.001	0.530	0.060
	Mastectomy
Chemotherapy	Yes	0.404	<0.001	0.013	<0.001
	No
Radiotherapy	Yes	0.049	<0.001	0.369	<0.001
	No

Abbreviations: AJCC, American Joint Committee on Cancer; DCIS, ductal carcinoma in situ; ER, estrogen receptor; HR, Hormone receptor; HER2, human epidermal receptor‐2; IDC, invasive ductal carcinoma; NAC, nipple‐areola complex; PD‐DCIS, Paget disease with ductal carcinoma in situ; PD‐IDC, Paget disease with invasive ductal carcinoma; PR, progesterone receptor; +, positive; and −, negative

^aHER2 status and molecular subtype data were available for only the patients who were diagnosed between 2010 and 2015.